DrugPatentWatch Database Preview

Abametapir - Generic Drug Details

« Back to Dashboard

What are the generic sources for abametapir and what is the scope of freedom to operate?

Abametapir is the generic ingredient in one branded drug marketed by Dr Reddys Labs Sa and is included in one NDA. There are five patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Abametapir has thirty-four patent family members in fifteen countries.

Summary for abametapir

International Patents:	34
US Patents:	5
Tradenames:	1
Applicants:	1
NDAs:	1
Bulk Api Vendors:	86
Clinical Trials:	5
Patent Applications:	335
DailyMed Link:	abametapir at DailyMed

Recent Clinical Trials for abametapir

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Hatchtech Pty Ltd	Phase 2
Hatchtech Pty Ltd	Phase 3
Accelovance	Phase 3

See all abametapir clinical trials

US Patents and Regulatory Information for abametapir

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Dr Reddys Labs Sa	XEGLYZE	abametapir	LOTION;TOPICAL	206966-001	Jul 24, 2020		RX	Yes	Yes			Y	Y
Dr Reddys Labs Sa	XEGLYZE	abametapir	LOTION;TOPICAL	206966-001	Jul 24, 2020		RX	Yes	Yes			Y
Dr Reddys Labs Sa	XEGLYZE	abametapir	LOTION;TOPICAL	206966-001	Jul 24, 2020		RX	Yes	Yes			Y
Dr Reddys Labs Sa	XEGLYZE	abametapir	LOTION;TOPICAL	206966-001	Jul 24, 2020		RX	Yes	Yes			Y
Dr Reddys Labs Sa	XEGLYZE	abametapir	LOTION;TOPICAL	206966-001	Jul 24, 2020		RX	Yes	Yes			Y

International Patents for abametapir

Country	Patent Number	Estimated Expiration
Japan	2008528449
Australia	2004257351
Spain	2483800
European Patent Office	3082424
European Patent Office	1653997
South Africa	200600164